Negin Hamidiyan

Master Student of #MedicalPhysics, interested in: PSMA PET/CT, Prostate Cancer, Image Analysis, and DL

[Negin Hamidiyan @Negin_hamidiyan]

@fatemehjal48452 Thanks azizam ☺️

[Negin Hamidiyan @Negin_hamidiyan]

At Rahe Aseman Nuclear Medicine Center today. Prepared a 25 mCi I-131 dose for thyroid cancer therapy.
Proud to be part of this field ☺️

[Negin Hamidiyan @Negin_hamidiyan]

Happy international day of #medicalphysics (7 Nov). #IDMP2025
We are ensuring imaging accuracy, radiation safety, and treatment precision.
Behind Every Beam, There's a Medical Physicist!

[JNM @JournalofNucMed]

PSMA PET staging is decreasing the use of surgical local therapy and increasing systemic therapy use in the Veterans Affairs system. https://t.co/1mCWUXnCFL

#NuclearMedicine #PETscan #ProstateCancer @stensy @megan_caram

[Eric Topol @EricTopol]

The prostate cancer PSA screening story over 23 years of follow-up for >166,000 participants: more detection, small reduction of mortality @NEJM https://t.co/MWckILe0Ni

[NEJM @NEJM]

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: https://t.co/iwULrhSglD

Editorial: Early Detection of Prostate Cancer — Time to Fish or Cut Bait https://t.co/G9Kmvrqrzj

[Michael Hofman @DrMHofman]

SPARC: The Standardised Prostate-specific Membrane Antigen PET-CT Analysis and Reporting Consensus

Open access: https://t.co/hrgzUOApxe @Uroweb
@EUplatinum

Bringing together all the PSMA guidelines into one modern consensus. Please use a template when reporting PSMA PET/CT !

Led by @ProfKHerrmann @bjartell & many many others including @drlouiseemmett @CzerninJohannes @stefanofanti4 @DrAGafita @thomashopemd @CaPsurvivorship @Silke_Gillessen @ProfJOSullivan @Albert0Briganti @philcornford @ProfHadaschik @piet_ost @sartor_oliver @declangmurphy

[Negin Hamidiyan @Negin_hamidiyan]

Happy International Day of Medical Physics!
Proud to be a part of this field as a medical physics student, working toward making a difference in healthcare.
#IDMP2024 #MedicalPhysics

[Michael Hofman @DrMHofman]

@cristian_udo: Evolving Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making

https://t.co/2G0JenEPm6
@IJROBP @_ShankarSiva @angela_jia_ @RenuEapen @DrAndrewLoblaw

[UroToday.com @urotoday]

A prospective pilot study investigating 18F rhPSMA-7.3 PET/MRI to detect recurrent disease and guide radiotherapy planning in pts with biochemically recurrent #ProstateCancer post-prostatectomy. @shilpa_surasi @MDAndersonNews. #ASTRO24 > https://t.co/W4kLNupXH4 @chavarriagaj

[Negin Hamidiyan @Negin_hamidiyan]

🌍🔬 On this #WorldCancerResearchDay, I'm proud to contribute to the fight against #ProstateCancer through innovative PET/CT PSMA imaging. Together, we can enhance early detection and improve treatment outcomes. Let's push for more research and awareness! 💙

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA) out on @TheLancetOncol and presented at #ESMO24

https://t.co/RTEaBcDwTy

The UpFrontPSMA phase 2 trial evaluated the use of Lutetium-177 [177Lu]Lu-PSMA-617 followed by docetaxel in patients with de-novo high-volume metastatic hormone-sensitive #ProstateCancer .Conducted at 11 Australian🇦🇺 hospitals, the trial randomly assigned patients to either the experimental treatment ([177Lu]Lu-PSMA-617 followed by docetaxel) or standard treatment (docetaxel alone). After 48 weeks, 41% of patients in the [177Lu]Lu-PSMA-617 group had undetectable PSA levels, compared to 16% in the docetaxel-only group.

The combination therapy demonstrated improved antitumor activity without added toxicity, suggesting [177Lu]Lu-PSMA-617 could benefit patients with hormone-sensitive metastatic prostate cancer.

@AzadOncology
@_vosko
@WeickhardtOnc
@J_Saghebi
@NattakornKnight
@drlouiseemmett
@declangmurphy
@DrMHofman

[Negin Hamidiyan @Negin_hamidiyan]

@DrMHofman @declangmurphy @DrAIravani @jusferdinandus PSMA has many advantages over conventional methods such as FDG, and this is quite obvious!

[Michael Hofman @DrMHofman]

In-transit back from #ESMO24 reflecting on my last attendance #ESMO17 where I had the pleasure to present our first 30 patient trial of Lutetium-177 PSMA-617. There was only a handful of nuclear medicine specialists at #ESMO17, and few oncologists had heard of PSMA.

Our @PeterMacCC @TheLancetOncol publication just topped 1000 citations:
https://t.co/nx6AGjKhwz

Fast forward to #ESMO24: amazing to see MANY nuclear medicine colleagues present and much interest in theranostics

The message is CLEAR: in order to progression nuCLEAR MEDICINE, we need prospective trials.

[Yu Yang Soon @yysoon01]

Why do the TheraP and VISION trials show different effects of Lu-177 PSMA on survival in advanced prostate cancer? It may be due to different comparison treatments.
https://t.co/2C93vaxngA
@MartinStockler @IanMarschner @DrMHofman @Prof_IanD @drlouiseemmett

[Negin Hamidiyan @Negin_hamidiyan]

@arian_madani Congratulations 🤩

[Negin Hamidiyan @Negin_hamidiyan]

@FSchaipp @umutsimsekli @TaylorAdrien @BachFrancis Congratulations 💐

[Physics In History @PhysInHistory]

A reminder: by Maria Skłodowska-Curie ✍️

Life is not easy for any of us. But what of that? We must have perseverance and above all confidence in ourselves. We must believe that we are gifted for something, and that this thing, at whatever cost, must be attained.

[nature @Nature]

Slow productivity: do fewer things, work at a natural pace and obsess over quality https://t.co/XbRH3YDwmu

[Prof. Feynman @ProfFeynman]

You keep on learning and learning, and pretty soon you learn something no one has learned before.